Trial · NCT07899632
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
NCT07899632, Phase 1, Phase 2, Not yet recruiting, Medsyn Biopharma, LLC
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors. Trials, record NCT07899632. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07899632
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
- NCT number
- NCT07899632
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 75 participants, estimated
- Lead sponsor
- Medsyn Biopharma, LLC
- Conditions
Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Hepatocellular Carcinoma Metastatic, Classical Hodgkin Lymphoma Relapsed, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome, Cutaneous T-Cell Lymphomas, Peripheral T-cell Lymphoma (PTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-Cell Large Granular Lymphocytic Leukemia
- Interventions
- MDSY-1240
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1 (Dose Escalation): Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days. | |
| Primary | Part 1 (Dose Escalation): Number of Participants With Serious Adverse Events (SAEs) | From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days | |
| Primary | Part 1 (Dose Escalation): Number of Participants With Adverse Events of Special Interest (AESIs) | From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days | |
| Primary | Part 1 (Dose Escalation): Number of Participants With Treatment-Related Adverse Events (TRAEs) | From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days | |
| Primary | Part 1 (Dose Escalation): Number of Participants With Dose Interruptions Due to Adverse Events | From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days | |
| Primary | Part 1 (Dose Escalation): Number of Participants With Treatment Discontinuations Due to Adverse Events | From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days | |
| Primary | Part 1 (Dose Escalation): Number of Participants With Infusion-Related Reactions (IRRs) | From informed consent (Cycle 0 Day -28) through 30 days after the last dose of study treatment (30-day safety follow-up). Each cycle is 28 days | |
| Primary | Part 1 (Dose Escalation): Number of Participants With Dose-Limiting Toxicities (DLTs) | During the Dose-Limiting Toxicity (DLT) evaluation period from Cycle 1 Day 1 through Day 22 of Cycle 1. | |
| Secondary | Part 1 (Dose Escalation): Maximum Observed Plasma Concentration (Cmax) of MDSY-1240 | PK samples collected from Cycle 1 Day 1 through Cycle 2 Day 1. | |
| Secondary | Part 1 (Dose Escalation): Time to Maximum Plasma Concentration (Tmax) of MDSY-1240 | PK samples collected from Cycle 1 Day 1 through Cycle 2 Day 1. |
1 to 10 of 23Source ClinicalTrials.gov
See all 23 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07899632
GET https://conductscience.org/api/trials/v1/NCT07899632/registered?page=2